Next Article in Journal
1-(2-Benzyl-1,5-dimethyl-6,7,8-trioxabicyclo[3.2.1]octan-2-yl)ethan-1-ol
Next Article in Special Issue
1-(4-{[3,5-bis({[3,5-Dimethyl-4-(4-methyl-3,5-dioxo-1,2,4-triazolidin-1-yl)-phenoxy]methyl})phenyl]methoxy}-2,6-dimethyl-phenyl)-4-methyl-1,2,4-triazolidine-3,5-dione
Previous Article in Journal
Aminophenyl-Aza-BODIPY
Previous Article in Special Issue
2-Benzyl-3-morpholino-7-(thiophen-2-yl)-6-(thiophen-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
 
 
Short Note
Peer-Review Record

1-[2-(1H-Pyrrole-2-carbonyl)phenyl]-3-(4-methoxyphenyl)urea

Molbank 2023, 2023(1), M1531; https://doi.org/10.3390/M1531
by Antonia G. Sarantou and George Varvounis *
Reviewer 1:
Molbank 2023, 2023(1), M1531; https://doi.org/10.3390/M1531
Submission received: 1 December 2022 / Revised: 9 December 2022 / Accepted: 17 December 2022 / Published: 22 December 2022
(This article belongs to the Collection Heterocycle Reactions)

Round 1

Reviewer 1 Report

The short note by Antonia G. Sarantou and George Varvounis entitled 1-[2-(1H-Pyrrole-2-carbonyl)phenyl]-3-(4-methoxyphenyl)urea describes the synthesis of the title compound.

In the introduction, the authors describe the numerous biological activities of N,N'-diarylureas, including FDA-approved drugs. In the sequel, the most representative methods for the synthesis of N,N'-diarylureas are presented. The introduction is well referenced, especially from the point of view of the synthesis of unsymmetrical ureas.

 

The results are clearly presented in Schemes 1 and 2 and in the accompanying text [compound numbers without IUPAC or trivial names should not be written in parentheses - please correct accordingly in the article]. The chemistry described supports the products formed in each synthesis step and is adequately supported by previous work of the author in this area.

The spectroscopic characterization of the final urea 7 is adequate and sufficiently explained. In my opinion, the intermediates on the way to the final urea product 7 are also adequately characterized. All spectroscopic data are also clearly presented in the ESI file.

 

The conclusions indicate the possibilities that this biologically active compound 7 offers for further investigation/ SAR-studies.

 

I could not find/verify the following reference

Papadaki, S.; Moschonas, I.; Peroulis, M.; Tatsidou, P.; Sarantou, A.; Tellis, C.; Varvounis, G.; Tselepis, A. Investigation of the 398 Antithrombotic and Antiplatelet Effect of a New Urea Analog, on Carotid Artery Thrombosis in Rabbits. Thromb. Res. 2016, 141, 399 Suppl. 1, S2. DOI: org/10.1016/S0049-3848(16)30386-3

 

Therefore, all references and their DOI need to be double-checked and corrected if necessary, especially reference number 30.

 

The synthetic procedures are written in an understandable and repeatable manner. Please use anhydrous THF instead of dry THF. Correct in the experimental section

 

If compounds 3-5 have already been reported, please provide the appropriate reference. I do not know the meaning of [2019CC7998(55)]? Compounds 3-5 are known compounds, therefore, they absolutely must be properly cited in the paper. Compounds 6 and 7 are new.

 

Additional comments are included in the PDF file of the manuscript.

 

With minor grammatical corrections, inclusion of the missing abstract, correction of references, and other minor errors, the Short Note by Antonia G. Sarantou and George Varvounis is suitable for publication.

 

Comments for author File: Comments.pdf

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop